Alluvi, previously BI 4744, presents a notable development in obesity treatment. This dual agonist targeting both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide sites demonstrates compelling https://alluvi-healthcare914491.wikihearsay.com/user